Table 2.
Comparison of Complete Response (CR) Among/Between Subgroups Divided by Demographic and Clinical Characteristics
| Parameters | N | Not CR | CR | p Value |
|---|---|---|---|---|
| Age | 0.086 | |||
| >60 years (n/%) | 122 | 100 (82.0) | 22 (18.0) | |
| <60 years (n/%) | 153 | 112 (73.2) | 41 (26.8) | |
| Gender | 0.501 | |||
| Male (n/%) | 228 | 174 (76.3) | 54 (23.7) | |
| Female (n/%) | 47 | 38 (80.9) | 9 (19.1) | |
| History of HB | 0.069 | |||
| Yes (n/%) | 228 | 171(75.0) | 57 (25.0) | |
| No (n/%) | 47 | 41 (87.2) | 6 (12.8) | |
| History of alcohol use | 0.726 | |||
| Yes (n/%) | 130 | 99 (76.2) | 31 (23.8) | |
| No (n/%) | 145 | 113 (77.9) | 32 (22.1) | |
| History of cirrhosis | 0.128 | |||
| Yes (n/%) | 165 | 122 (73.9) | 43 (26.1) | |
| No (n/%) | 110 | 90 (81.8) | 20 (18.2) | |
| Tumor distribution | 0.114 | |||
| Multifocal disease (n/%) | 180 | 144 (80.0) | 36 (20.0) | |
| Unifocal disease (n/%) | 95 | 68 (71.6) | 27 (28.4) | |
| Tumor location | 0.246 | |||
| Left liver (n/%) | 42 | 29 (69.0) | 13 (31.0) | |
| Right liver (n/%) | 144 | 110 (76.4) | 34 (23.6) | |
| Bilobar (n/%) | 89 | 73 (82.0) | 16 (18.0) | |
| Largest nodule size | 0.004 | |||
| ≥5 cm (n/%) | 135 | 114 (84.4) | 21 (15.6) | |
| <5 cm (n/%) | 140 | 98 (70.0) | 42 (30.0) | |
| Portal vein invasion | <0.001 | |||
| Yes (n/%) | 82 | 76 (92.7) | 6 (7.3) | |
| No (n/%) | 193 | 136 (70.5) | 57 (29.5) | |
| Hepatic vein invasion | 0.060 | |||
| Yes (n/%) | 37 | 33 (89.2) | 4 (10.8) | |
| No (n/%) | 238 | 179 (75.2) | 59 (24.8) | |
| ECOG performance status | 0.125 | |||
| 0 (n/%) | 172 | 128 (74.4) | 44 (25.6) | |
| 1 (n/%) | 83 | 66 (79.5) | 17 (20.5) | |
| 2 (n/%) | 14 | 12 (85.7) | 2 (14.3) | |
| 3 (n/%) | 6 | 6 (100.0) | 0 (0.0) | |
| Child–Pugh stage | 0.147 | |||
| A (n/%) | 228 | 172 (75.4) | 56 (24.6) | |
| B (n/%) | 45 | 38 (84.4) | 7 (15.6) | |
| C (n/%) | 2 | 2 (100.0) | 0 (0.0) | |
| BCLC stage | 0.019 | |||
| 0 (n/%) | 1 | 1 (100) | 0 (0) | |
| A (n/%) | 67 | 43 (64.2) | 24 (35.8) | |
| B (n/%) | 108 | 87 (80.6) | 21 (19.4) | |
| C (n/%) | 98 | 80 (81.6) | 18 (18.4) | |
| D (n/%) | 1 | 1 (100) | 0 (0) | |
| Cycles of DEB-TACE treatment | 0.999 | |||
| One cycle (n/%) | 227 | 175 (77.1) | 52 (22.9) | |
| Two or more cycles (n/%) | 48 | 37 (77.1) | 11 (22.9) | |
| Previous cTACE treatment | 0.390 | |||
| Yes (n/%) | 118 | 124 (79.0) | 33 (21.0) | |
| No (n/%) | 157 | 88 (74.6) | 30 (25.4) | |
| Previous surgery | 0.636 | |||
| Yes (n/%) | 68 | 51 (75.0) | 17 (25.0) | |
| No (n/%) | 207 | 161 (77.8) | 46 (22.2) | |
| Previous systematic chemotherapy | 0.389 | |||
| Yes (n/%) | 8 | 5 (62.5) | 3 (37.5) | |
| No (n/%) | 267 | 207 (77.5) | 60 (22.5) | |
| Previous radiofrequency ablation | 0.167 | |||
| Yes (n/%) | 36 | 31 (86.1) | 5 (13.9) | |
| No (n/%) | 239 | 181 (75.7) | 58 (24.3) | |
| Previous targeted therapy | 1.000 | |||
| Yes (n/%) | 8 | 6 (75.0) | 2 (25.0) | |
| No (n/%) | 267 | 206 (77.2) | 61 (22.8) | |
| Combination of ordinary embolization agent | 0.078 | |||
| Yes (n/%) | 100 | 83 (83.0) | 17 (17.0) | |
| No (n/%) | 175 | 129 (73.7) | 46 (26.3) |
Data are presented as count (%). Comparison between two groups was determined by chi-square test. A value of p < 0.05 was considered significant.